641 - Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Resistant to Commonly Used Oral Therapies for UTI in the US (2019-2020)

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

SA

SJ Ryan Arends, PhD

Principal Scientist
JMI Laboratories
North Liberty, Iowa, United States
JK

John H. Kimbrough, PhD

Research Scientist
JMI Laboratories
North Liberty, Iowa, United States
VK

Valerie Kantro, BA

Molecular Laboratory Manager
JMI Laboratories
North Liberty, Iowa, United States
DB

Deborah Butler, PharmD

VP & Head of Emerging Markets Regulatory Affairs at GSK
GSK
London, England, United Kingdom
NS

Nicole E. Scangarella-Oman, MS

Scientific Director
GlaxoSmithKline plc.
Collegeville, Pennsylvania, United States
JS

Jennifer M. Streit, BS, MT(ASCP)

Surveillance Manager
JMI Laboratories
North Liberty, Iowa, United States
Mariana Castanheira, PhD

Chief Scientific Officer
JMI Laboratories
North Liberty, Iowa, United States